P28-10 Survival difference between EGFR exon 19 deletion and exon 21 mutation in advanced non-small cell lung cancer patients

Abstract

Epidermal growth factor receptor (EGFR) mutation status is a good predictor of response to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). The existing data on the difference in survival outcome between EGFR sensitizing mutations are limited and conflicting. This study aims to determine the survival difference between EGFR exon 19 deletion and exon 21 mutation in advanced NSCLC patients.